Aquestive Therapeutics
AQST
117 hedge funds and large institutions have $232M invested in Aquestive Therapeutics in 2024 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 41 increasing their positions, 23 reducing their positions, and 17 closing their positions.
358% more call options, than puts
Call options by funds: $5.75M | Put options by funds: $1.25M
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
110% more capital invested
Capital invested by funds: $111M → $232M (+$122M)
78% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 23
19% more funds holding
Funds holding: 98 → 117 (+19)
4.61% more ownership
Funds ownership: 46.73% → 51.35% (+4.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$6.99M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.74M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$2.71M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$2.13M |
| 2 |
Renaissance Technologies
New York
|
-$1.82M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.7M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$1.17M |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$768K |
AQST Hedge Fund Activity: Q3 2024 in Review
117 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q3 2024, worth a combined $232M — up 110% from $111M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AQST positions and 17 closed out — a net gain of 20 holders — while 41 added to existing stakes and 23 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $6.99M. The largest seller was Nuveen, cutting an estimated $2.13M.
- 117 institutional investors held Aquestive Therapeutics (AQST) as of Q3 2024, up from 98 in Q2 2024.
- Funds reported $232M of Aquestive Therapeutics stock for Q3 2024, up 110% quarter-over-quarter.
- 37 funds opened new Aquestive Therapeutics positions in Q3 2024 and 17 closed out, a net change of +20 holders.
- The largest Aquestive Therapeutics buyer in Q3 2024 was MPM BioImpact, an estimated $6.99M added.
- The largest Aquestive Therapeutics seller in Q3 2024 was Nuveen, an estimated $2.13M sold.
Based on aggregated 13F filings for Q3 2024.